Hi Joao, you can find these information in the "Clinical Handbook of Psychotropic Drugs." Edited by Virani A. et al. (http://chpd.hogrefe.com/). It is a really informative book. I have the 18th edition on my hand.
The most reliable way of comparing dose-equivalents of various medications is by using DDD (defined daily dose). You can read about DDD here: http://www.whocc.no/ddd/definition_and_general_considera/
There is a regularly updated web page providing DDD for most medications, you will find psychotropic medications here: http://www.whocc.no/atc_ddd_index/?code=N&showdescription=yes
This question has hardly been studied at all and should be clarified in terms of what you mean by "mood stabilizer". There are several studies which have looked at this in terms of acute mania treatments. For example, Gelenberg and Kane found monotherapy Li levels of 0.8 - 1.0 more efficacious than 0.4 - 0.6. Our group found haloperidol 25 mg/d more efficacious than 5 mg/d but only when used as monotherapy and not when combined with lithium. Atypical antipsychotic studies in acute mania have largely either been flexible dose or single dose. To my knowledge, there is no study comparing doses of an atypical antipsychotic in acute mania. In the acute mania studies where atypical antipsychotics were used with either lithium or valproate, the lithium or valproate has always been flexible dose, with occasional studies requiring a minimum blood level.
For acute bipolar depression, one early study by Calabrese showed that lamotrigine 150 mg/d was superior to 50 mg/d but subsequent studies of lamotrigine raise the question of whether lamotrigine is actually efficacious in acute depression. The olanzapine studies were all flexible dose. The quetiapine studies compared 2 doses but found no difference between doses.
in bipolar maintenance, the story is even less clear as virtually all studies have been flexible dose.
Thus, basically your question has not been studied. However, if you look at how clinicians are practicing, you will find that practice patterns differ tremendously according to setting and are confounded by monotherapy vs. combination therapies. As an example, even among the investigators in the Depakote maintenance trial, there was complete disagreement in how Depakote should be dosed, with some investigators shooting for a blood level of around 65 and others 95.
Hope this is helpful.
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology